nach oben

Journal of Neuro-Oncology

Erschienen in:

05.01.2024 | Review

Understanding current experimental models of glioblastoma-brain microenvironment interactions

verfasst von: Niket Yadav, Benjamin W. Purow

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Glioblastoma (GBM) is a common and devastating primary brain tumor, with median survival of 16–18 months after diagnosis in the setting of substantial resistance to standard-of-care and inevitable tumor recurrence. Recent work has implicated the brain microenvironment as being critical for GBM proliferation, invasion, and resistance to treatment. GBM does not operate in isolation, with neurons, astrocytes, and multiple immune populations being implicated in GBM tumor progression and invasiveness. The goal of this review article is to provide an overview of the available in vitro, ex vivo, and in vivo experimental models for assessing GBM-brain interactions, as well as discuss each model’s relative strengths and limitations. Current in vitro models discussed will include 2D and 3D co-culture platforms with various cells of the brain microenvironment, as well as spheroids, whole organoids, and models of fluid dynamics, such as interstitial flow. An overview of in vitro and ex vivo organotypic GBM brain slices is also provided. Finally, we conclude with a discussion of the various in vivo rodent models of GBM, including xenografts, syngeneic grafts, and genetically-engineered models of GBM.

Abdolahi S, Ghazvinian Z, Muhammadnejad S et al (2022) Patient-derived xenograft (PDX) models, applications and challenges in cancer research. J Transl Med 20(1):206. https://doi.org/10.1186/s12967-022-03405-8CrossRefPubMedPubMedCentral

Adhikaree J, Franks HA, Televantos C et al (2019) Impaired circulating myeloid CD1c + dendritic cell function in human glioblastoma is restored by p38 inhibition - implications for the next generation of DC vaccines. Oncoimmunology 8(7):1593803. https://doi.org/10.1080/2162402X.2019.1593803CrossRefPubMedPubMedCentral

Akkari L, Bowman RL, Tessier J et al (2020) Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance. Sci Transl Med 12(552). https://doi.org/10.1126/scitranslmed.aaw7843

Alban TJ, Bayik D, Otvos B et al (2020) Glioblastoma myeloid-derived suppressor cell Subsets Express Differential Macrophage Migration Inhibitory factor receptor profiles that can be targeted to reduce Immune suppression. Front Immunol 11:1191. https://doi.org/10.3389/fimmu.2020.01191CrossRefPubMedPubMedCentral

Alcaniz J, Winkler L, Dahlmann M et al (2023) Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures. Front Oncol 13:1129627. https://doi.org/10.3389/fonc.2023.1129627CrossRefPubMedPubMedCentral

Andersen BM, Faust Akl C, Wheeler MA et al (2021) Glial and myeloid heterogeneity in the brain tumour microenvironment. Nat Rev Cancer 21(12):786–802. https://doi.org/10.1038/s41568-021-00397-3CrossRefPubMedPubMedCentral

Anido J, Saez-Borderias A, Gonzalez-Junca A et al (2010) TGF-beta receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating Cell Population in Human Glioblastoma. Cancer Cell 18(6):655–668. https://doi.org/10.1016/j.ccr.2010.10.023CrossRefPubMed

Arabzade A, Zhao Y, Varadharajan S et al (2021) ZFTA-RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma. Cancer Discov 11(9):2200–2215. https://doi.org/10.1158/2159-8290.CD-20-1066CrossRefPubMedPubMedCentral

Bassil R, Shields K, Granger K et al (2021) Improved modeling of human AD with an automated culturing platform for iPSC neurons, astrocytes and microglia. Nat Commun 12(1):5220. https://doi.org/10.1038/s41467-021-25344-6ADSCrossRefPubMedPubMedCentral

10.

Bausart M, Preat V, Malfanti A (2022) Immunotherapy for glioblastoma: the promise of combination strategies. J Exp Clin Cancer Res 41(1):35. https://doi.org/10.1186/s13046-022-02251-2CrossRefPubMedPubMedCentral

11.

Bian S, Repic M, Guo Z et al (2018) Genetically engineered cerebral organoids model Brain Tumor formation. Nat Methods 15(8):631–639. https://doi.org/10.1038/s41592-018-0070-7CrossRefPubMedPubMedCentral

12.

Binello E, Qadeer ZA, Kothari HP et al (2012) Stemness of the CT-2A Immunocompetent Mouse Brain Tumor Model: characterization in Vitro. J Cancer 3:166–174. https://doi.org/10.7150/jca.4149CrossRefPubMedPubMedCentral

13.

Bodmer S, Strommer K, Frei K et al (1989) Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol 143(10):3222–3229CrossRefPubMed

14.

Bolli E, Scherger M, Arnouk SM et al (2021) Targeted repolarization of Tumor-Associated macrophages via Imidazoquinoline-Linked Nanobodies. Adv Sci (Weinh) 8(10):2004574. https://doi.org/10.1002/advs.202004574CrossRefPubMed

15.

Brandao M, Simon T, Critchley G et al (2019) Astrocytes, the rising stars of the glioblastoma microenvironment. Glia 67(5):779–790. https://doi.org/10.1002/glia.23520CrossRefPubMed

16.

Bruns J, Egan T, Mercier P et al (2023) Glioblastoma spheroid growth and chemotherapeutic responses in single and dual-stiffness hydrogels. Acta Biomater 163:400–414. https://doi.org/10.1016/j.actbio.2022.05.048CrossRefPubMed

17.

Calori IR, Alves SR, Bi H et al (2022) Type-I Collagen/Collagenase modulates the 3D structure and behavior of Glioblastoma Spheroid models. ACS Appl Bio Mater 5(2):723–733. https://doi.org/10.1021/acsabm.1c01138CrossRefPubMed

18.

Cancer Genome Atlas Research (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216):1061–1068. https://doi.org/10.1038/nature07385ADSCrossRef

19.

Carlson JC, Cantu Gutierrez M, Lozzi B et al (2021) Identification of diverse Tumor endothelial cell populations in malignant glioma. Neuro Oncol 23(6):932–944. https://doi.org/10.1093/neuonc/noaa297CrossRefPubMed

20.

Cheema TA, Wakimoto H, Fecci PE et al (2013) Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc Natl Acad Sci U S A 110(29):12006–12011. https://doi.org/10.1073/pnas.1307935110ADSCrossRefPubMedPubMedCentral

21.

Chen F, LoTurco J (2012) A method for stable transgenesis of radial glia lineage in rat neocortex by piggyBac mediated transposition. J Neurosci Methods 207(2) 172 – 80. https://doi.org/10.1016/j.jneumeth.2012.03.016

22.

Chen ML, Pittet MJ, Gorelik L et al (2005) Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci U S A 102(2):419–424. https://doi.org/10.1073/pnas.0408197102ADSCrossRefPubMed

23.

Chen S, Lai SWT, Brown CE et al (2021) Harnessing and enhancing macrophage phagocytosis for Cancer Therapy. Front Immunol 12:635173. https://doi.org/10.3389/fimmu.2021.635173CrossRefPubMedPubMedCentral

24.

Chen D, Varanasi SK, Hara T et al (2023) CTLA-4 blockade induces a microglia-Th1 cell partnership that stimulates microglia phagocytosis and anti-tumor function in glioblastoma. Immunity 56(9):2086–2104e8. https://doi.org/10.1016/j.immuni.2023.07.015CrossRefPubMed

25.

Chiavari M, Ciotti GMP, Navarra P et al (2019) Pro-inflammatory activation of a New Immortalized Human Microglia Cell line. Brain Sci 9(5). https://doi.org/10.3390/brainsci9050111

26.

Civita P, D ML, Pilkington GJ (2019) Pre-clinical drug testing in 2D and 3D human in Vitro models of Glioblastoma incorporating non-neoplastic astrocytes: Tunneling Nano tubules and mitochondrial transfer modulates cell behavior and therapeutic respons. Int J Mol Sci 20(23). https://doi.org/10.3390/ijms20236017

27.

Coniglio S, Miller I, Symons M et al (2016) Coculture assays to study macrophage and Microglia Stimulation of Glioblastoma Invasion. J Vis Exp 116https://doi.org/10.3791/53990

28.

Cornelison RC, Brennan CE, Kingsmore KM et al (2018) Convective forces increase CXCR4-dependent glioblastoma cell invasion in GL261 murine model. Sci Rep 8(1):17057. https://doi.org/10.1038/s41598-018-35141-9ADSCrossRefPubMedPubMedCentral

29.

Cornelison RC, Yuan JX, Tate KM et al (2022) A patient-designed tissue-engineered model of the infiltrative glioblastoma microenvironment. NPJ Precis Oncol 6(1):54. https://doi.org/10.1038/s41698-022-00290-8CrossRefPubMedPubMedCentral

30.

Costa B, Eisemann T, Strelau J et al (2019) Intratumoral platelet aggregate formation in a murine preclinical glioma model depends on podoplanin expression on Tumor cells. Blood Adv 3(7):1092–1102. https://doi.org/10.1182/bloodadvances.2018015966CrossRefPubMedPubMedCentral

31.

Cui X, Wang Q, Zhou J et al (2021) Single-cell transcriptomics of Glioblastoma reveals a unique Tumor Microenvironment and potential immunotherapeutic target against Tumor-Associated Macrophage. Front Oncol 11:710695. https://doi.org/10.3389/fonc.2021.710695CrossRefPubMedPubMedCentral

32.

D’Alessio A, Proietti G, Sica G et al (2019) Pathological and molecular features of Glioblastoma and its Peritumoral tissue. Cancers (Basel) 11(4). https://doi.org/10.3390/cancers11040469

33.

Decotret LR, Shi R, Thomas KN et al (2023) Development and validation of an advanced ex vivo brain slice invasion assay to model glioblastoma cell invasion into the complex brain microenvironment. Front Oncol 13:976945. https://doi.org/10.3389/fonc.2023.976945CrossRefPubMedPubMedCentral

34.

Douvaras P, Sun B, Wang M et al (2017) Directed differentiation of human pluripotent stem cells to Microglia. Stem Cell Reports 8(6):1516–1524. https://doi.org/10.1016/j.stemcr.2017.04.023CrossRefPubMedPubMedCentral

35.

Duval K, Grover H, Han LH et al (2017) Modeling physiological events in 2D vs. 3D cell culture. Physiol (Bethesda) 32(4):266–277. https://doi.org/10.1152/physiol.00036.2016CrossRef

36.

Eisemann T, Costa B, Strelau J et al (2018) An advanced glioma cell invasion assay based on organotypic brain slice cultures. BMC Cancer 18(1):103. https://doi.org/10.1186/s12885-018-4007-4CrossRefPubMedPubMedCentral

37.

Engblom C, Pfirschke C, Pittet MJ (2016) The role of myeloid cells in cancer therapies. Nat Rev Cancer 16(7) 447 – 62. https://doi.org/10.1038/nrc.2016.54

38.

Eramo A, Ricci-Vitiani L, Zeuner A et al (2006) Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 13(7):1238–1241. https://doi.org/10.1038/sj.cdd.4401872CrossRefPubMed

39.

Fedorova V, Pospisilova V, Vanova T et al (2023) Glioblastoma and cerebral organoids: development and analysis of an in vitro model for glioblastoma migration. Mol Oncol 17(4):647–663. https://doi.org/10.1002/1878-0261.13389CrossRefPubMedPubMedCentral

40.

Feng SW, Wu ZS, Chiu YL et al (2023) Exploring the functional roles of Telomere Maintenance 2 in the tumorigenesis of Glioblastoma Multiforme and Drug Responsiveness to Temozolomide. Int J Mol Sci 24(11). https://doi.org/10.3390/ijms24119256

41.

Filley AC, Henriquez M, Dey M (2017) Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget 8(53):91779–91794. https://doi.org/10.18632/oncotarget.21586CrossRefPubMedPubMedCentral

42.

Flores C, Pham C, Snyder D et al (2015) Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas. Oncoimmunology 4(3):e994374. https://doi.org/10.4161/2162402X.2014.994374CrossRefPubMedPubMedCentral

43.

Genoud V, Marinari E, Nikolaev SI et al (2018) Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models. Oncoimmunology 7(12):e1501137. https://doi.org/10.1080/2162402X.2018.1501137CrossRefPubMedPubMedCentral

44.

Geribaldi-Doldan N, Fernandez-Ponce C, Quiroz RN et al (2020) The role of Microglia in Glioblastoma. Front Oncol 10:603495. https://doi.org/10.3389/fonc.2020.603495CrossRefPubMed

45.

Glasgow SM, Zhu W, Stolt CC et al (2014) Mutual antagonism between Sox10 and NFIA regulates diversification of glial lineages and glioma subtypes. Nat Neurosci 17(10):1322–1329. https://doi.org/10.1038/nn.3790CrossRefPubMedPubMedCentral

46.

Gomez-Oliva R, Dominguez-Garcia S, Carrascal L et al (2020) Evolution of experimental models in the study of Glioblastoma: toward finding efficient treatments. Front Oncol 10:614295. https://doi.org/10.3389/fonc.2020.614295CrossRefPubMed

47.

Goudarzi S, Rivera A, Butt AM et al (2016) Gas6 promotes oligodendrogenesis and myelination in the adult Central Nervous System and after Lysolecithin-Induced demyelination. ASN Neuro 8(5). https://doi.org/10.1177/1759091416668430

48.

Guillot A, Tacke F (2019) Liver macrophages: Old dogmas and New insights. Hepatol Commun 3(6):730–743. https://doi.org/10.1002/hep4.1356CrossRefPubMedPubMedCentral

49.

Guyon J, Strale PO, Romero-Garmendia I et al (2021) Co-culture of Glioblastoma Stem-like cells on patterned neurons to Study Migration and Cellular interactions. J Vis Exp 168. https://doi.org/10.3791/62213

50.

Haddad AF, Young JS, Amara D et al (2021) Mouse models of glioblastoma for the evaluation of novel therapeutic strategies. Neurooncol Adv 3(1):vdab100. https://doi.org/10.1093/noajnl/vdab100

51.

Hambardzumyan D, Parada LF, Holland EC et al (2011) Genetic modeling of gliomas in mice: new tools to tackle old problems. Glia 59(8):1155–1168. https://doi.org/10.1002/glia.21142CrossRefPubMedPubMedCentral

52.

Hara T, Chanoch-Myers R, Mathewson ND et al (2021) Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma. Cancer Cell 39(6):779–792e11. https://doi.org/10.1016/j.ccell.2021.05.002CrossRefPubMedPubMedCentral

53.

Henrik Heiland D, Ravi VM, Behringer SP et al (2019) Tumor-associated reactive astrocytes aid the evolution of immunosuppressive environment in glioblastoma. Nat Commun 10(1):2541. https://doi.org/10.1038/s41467-019-10493-6ADSCrossRefPubMedPubMedCentral

54.

Hess KR, Broglio KR, Bondy ML (2004) Adult glioma incidence trends in the United States, 1977–2000. Cancer 101(10):2293–2299. https://doi.org/10.1002/cncr.20621CrossRefPubMed

55.

Hide T, Komohara Y, Miyasato Y et al (2018) Oligodendrocyte Progenitor Cells and Macrophages/Microglia Produce Glioma Stem Cell Niches at the Tumor Border EBioMedicine, 30: p. 94–104. https://doi.org/10.1016/j.ebiom.2018.02.024

56.

Hornschemeyer J, Kirschstein T, Reichart G et al (2022) Studies on Biological and Molecular effects of small-molecule kinase inhibitors on human glioblastoma cells and organotypic brain slices. Life (Basel) 12(8). https://doi.org/10.3390/life12081258

57.

Hsu SPC, Chen YC, Chiang HC et al (2020) Rapamycin and hydroxychloroquine combination alters macrophage polarization and sensitizes glioblastoma to immune checkpoint inhibitors. J Neurooncol 146(3):417–426. https://doi.org/10.1007/s11060-019-03360-3CrossRefPubMedPubMedCentral

58.

Humpel C (2015) Organotypic brain slice cultures: a review. Neuroscience 305:86–98. https://doi.org/10.1016/j.neuroscience.2015.07.086CrossRefPubMed

59.

Huse JT, Holland EC (2009) Genetically engineered mouse models of Brain cancer and the promise of preclinical testing. Brain Pathol 19(1):132–143. https://doi.org/10.1111/j.1750-3639.2008.00234.xCrossRefPubMed

60.

Hutter G, Theruvath J, Graef CM et al (2019) Microglia are effector cells of CD47-SIRPalpha antiphagocytic axis disruption against glioblastoma. Proc Natl Acad Sci U S A 116(3):997–1006. https://doi.org/10.1073/pnas.1721434116ADSCrossRefPubMedPubMedCentral

61.

Jacob F, Salinas RD, Zhang DY et al (2020) A patient-derived Glioblastoma Organoid Model and Biobank recapitulates Inter- and intra-tumoral heterogeneity. Cell 180(1):188–204e22. https://doi.org/10.1016/j.cell.2019.11.036CrossRefPubMed

62.

Jensen SS, Meyer M, Petterson SA et al (2016) Establishment and characterization of a Tumor Stem Cell-based Glioblastoma Invasion Model. PLoS ONE 11(7):e0159746. https://doi.org/10.1371/journal.pone.0159746CrossRefPubMedPubMedCentral

63.

Jimenez-Dinamarca I, Reyes-Lizana R, Lemunao-Inostroza Y et al (2022) GABAergic regulation of Astroglial Gliotransmission through Cx43 Hemichannels. Int J Mol Sci 23(21). https://doi.org/10.3390/ijms232113625

64.

Jin MZ, Han RR, Qiu GZ et al (2018) Organoids: an intermediate modeling platform in precision oncology. Cancer Lett 414:174–180. https://doi.org/10.1016/j.canlet.2017.11.021CrossRefPubMed

65.

Joseph JV, Magaut CR, Storevik S et al (2022) TGF-beta promotes microtube formation in glioblastoma through thrombospondin 1. Neuro Oncol 24(4):541–553. https://doi.org/10.1093/neuonc/noab212CrossRefPubMed

66.

Kapalczynska M, Kolenda T, Przybyla W et al (2018) 2D and 3D cell cultures - a comparison of different types of cancer cell cultures. Arch Med Sci 14(4):910–919. https://doi.org/10.5114/aoms.2016.63743CrossRefPubMed

67.

Kawashima T, Yashiro M, Kasashima H et al (2019) Oligodendrocytes Up-regulate the invasive activity of Glioblastoma Cells via the Angiopoietin-2 Signaling Pathway. Anticancer Res 39(2):577–584. https://doi.org/10.21873/anticanres.13150CrossRefPubMed

68.

Kerstetter-Fogle AE, Harris PLR, Brady-Kalnay SM et al (2020) Generation of Glioblastoma patient-derived intracranial xenografts for preclinical studies. Int J Mol Sci 21(14). https://doi.org/10.3390/ijms21145113

69.

Khalsa JK, Cheng N, Keegan J et al (2020) Immune phenotyping of diverse syngeneic murine brain tumors identifies immunologically distinct types. Nat Commun 11(1):3912. https://doi.org/10.1038/s41467-020-17704-5CrossRefPubMedPubMedCentral

70.

Khan MI, Jeong ES, Khan MZ et al (2023) Stem cells-derived exosomes alleviate neurodegeneration and Alzheimer’s pathogenesis by ameliorating neuroinflamation, and regulating the associated molecular pathways. Sci Rep 13(1):15731. https://doi.org/10.1038/s41598-023-42485-4ADSCrossRefPubMedPubMedCentral

71.

Kim GB, Rincon Fernandez Pacheco D, Saxon D et al (2019) Rapid Generation of Somatic Mouse Mosaics with Locus-Specific, Stably Integrated Transgenic Elements. Cell 179(1):251–267e24. https://doi.org/10.1016/j.cell.2019.08.013CrossRefPubMedPubMedCentral

72.

Kingsmore KM, Logsdon DK, Floyd DH et al (2016) Interstitial flow differentially increases patient-derived glioblastoma stem cell invasion via CXCR4, CXCL12, and CD44-mediated mechanisms. Integr Biol (Camb) 8(12):1246–1260. https://doi.org/10.1039/c6ib00167jCrossRefPubMed

73.

Lancaster MA, Renner M, Martin CA et al (2013) Cerebral organoids model human brain development and microcephaly. Nature 501(7467):373–379. https://doi.org/10.1038/nature12517ADSCrossRefPubMed

74.

Lee J, Kotliarova S, Kotliarov Y et al (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9(5):391–403. https://doi.org/10.1016/j.ccr.2006.03.030CrossRefPubMed

75.

Leite DM, Zvar Baskovic B, Civita P et al (2020) A human co-culture cell model incorporating microglia supports glioblastoma growth and migration, and confers resistance to cytotoxics. FASEB J 34(1):1710–1727. https://doi.org/10.1096/fj.201901858RRCrossRefPubMed

76.

Lenting K, Verhaak R, Ter Laan M et al (2017) Glioma: experimental models and reality. Acta Neuropathol 133(2):263–282. https://doi.org/10.1007/s00401-017-1671-4CrossRefPubMedPubMedCentral

77.

Letchuman V, Ampie L, Shah AH et al (2022) Syngeneic murine glioblastoma models: reactionary immune changes and immunotherapy intervention outcomes. Neurosurg Focus 52(2):E5. https://doi.org/10.3171/2021.11.FOCUS21556CrossRefPubMed

78.

Li C, Xu X, Wei S et al (2021) Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer. J Immunother Cancer 9(1). https://doi.org/10.1136/jitc-2020-001341

79.

Li X, Guo X, Ling J et al (2021) Nanomedicine-based cancer immunotherapies developed by reprogramming tumor-associated macrophages. Nanoscale 13(9):4705–4727. https://doi.org/10.1039/d0nr08050kCrossRefPubMed

80.

Lim M, Xia Y, Bettegowda C et al (2018) Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol 15(7):422–442. https://doi.org/10.1038/s41571-018-0003-5CrossRefPubMed

81.

Linkous A, Balamatsias D, Snuderl M et al (2019) Modeling patient-derived glioblastoma with cerebral organoids. Cell Rep 26(12):3203–3211e5. https://doi.org/10.1016/j.celrep.2019.02.063CrossRefPubMedPubMedCentral

82.

Liu P, Griffiths S, Veljanoski D et al (2021) Preclinical models of glioblastoma: limitations of current models and the promise of new developments. Expert Rev Mol Med 23:e20. https://doi.org/10.1017/erm.2021.20CrossRefPubMed

83.

Loras A, Gonzalez-Bonet LG, Gutierrez-Arroyo JL et al (2023) Neural stem cells as potential glioblastoma cells of Origin. Life (Basel) 13(4). https://doi.org/10.3390/life13040905

84.

Lu Y, Jiang F, Zheng X et al (2011) TGF-beta1 promotes motility and invasiveness of glioma cells through activation of ADAM17. Oncol Rep 25(5):1329–1335. https://doi.org/10.3892/or.2011.1195CrossRefPubMed

85.

Maas RR, Soukup K, Fournier N et al (2023) The local microenvironment drives activation of neutrophils in human brain tumors. Cell. https://doi.org/10.1016/j.cell.2023.08.043CrossRefPubMed

86.

Marques-Torrejon MA, Gangoso E, Pollard SM (2018) Modelling glioblastoma tumour-host cell interactions using adult brain organotypic slice co-culture. Dis Model Mech 11(2). https://doi.org/10.1242/dmm.031435

87.

Martinez-Murillo R, Martinez A (2007) Standardization of an orthotopic mouse Brain Tumor model following transplantation of CT-2A astrocytoma cells. Histol Histopathol 22(12):1309–1326. https://doi.org/10.14670/HH-22.1309CrossRefPubMed

88.

Marumoto T, Tashiro A, Friedmann-Morvinski D et al (2009) Development of a novel mouse glioma model using lentiviral vectors. Nat Med 15(1):110–116. https://doi.org/10.1038/nm.1863CrossRefPubMedPubMedCentral

89.

McCarthy RC, Lu DY, Alkhateeb A et al (2016) Characterization of a novel adult murine immortalized microglial cell line and its activation by amyloid-beta. J Neuroinflammation 13:21. https://doi.org/10.1186/s12974-016-0484-zCrossRefPubMedPubMedCentral

90.

Melissaridou S, Wiechec E, Magan M et al (2019) The effect of 2D and 3D cell cultures on treatment response, EMT profile and stem cell features in Head and Neck cancer. Cancer Cell Int 19:16. https://doi.org/10.1186/s12935-019-0733-1CrossRefPubMedPubMedCentral

91.

Merz F, Gaunitz F, Dehghani F et al (2013) Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments. Neuro Oncol 15(6):670–681. https://doi.org/10.1093/neuonc/not003CrossRefPubMedPubMedCentral

92.

Merzak A, McCrea S, Koocheckpour S et al (1994) Control of human glioma cell growth, migration and invasion in vitro by transforming growth factor beta 1. Br J Cancer 70(2):199–203. https://doi.org/10.1038/bjc.1994.280CrossRefPubMedPubMedCentral

93.

Minami N, Maeda Y, Shibao S et al (2017) Organotypic brain explant culture as a drug evaluation system for malignant brain tumors. Cancer Med 6(11):2635–2645. https://doi.org/10.1002/cam4.1174CrossRefPubMedPubMedCentral

94.

Munson JM, Bellamkonda RV, Swartz MA (2013) Interstitial flow in a 3D microenvironment increases glioma invasion by a CXCR4-dependent mechanism. Cancer Res 73(5):1536–1546. https://doi.org/10.1158/0008-5472.CAN-12-2838CrossRefPubMed

95.

Nagamoto-Combs K, Kulas J, Combs CK (2014) A novel cell line from spontaneously immortalized murine microglia. J Neurosci Methods 233:187–198. https://doi.org/10.1016/j.jneumeth.2014.05.021CrossRefPubMedPubMedCentral

96.

Narvaez-Perez LF, Paz-Bermudez F, Avalos-Fuentes JA et al (2023) CRISPR/sgRNA-directed synergistic activation mediator (SAM) as a therapeutic tool for Parkinson s Disease. Gene Ther. https://doi.org/10.1038/s41434-023-00414-0CrossRefPubMedPubMedCentral

97.

Nishida-Aoki N, Gujral TS (2022) Polypharmacologic reprogramming of Tumor-Associated macrophages toward an inflammatory phenotype. Cancer Res 82(3):433–446. https://doi.org/10.1158/0008-5472.CAN-21-1428CrossRefPubMed

98.

Noffsinger B, Witter A, Sheybani N et al (2021) Technical choices significantly alter the adaptive immune response against immunocompetent murine gliomas in a model-dependent manner. J Neurooncol 154(2):145–157. https://doi.org/10.1007/s11060-021-03822-7CrossRefPubMedPubMedCentral

99.

Ogawa J, Pao GM, Shokhirev MN et al (2018) Glioblastoma model using human cerebral organoids. Cell Rep 23(4):1220–1229. https://doi.org/10.1016/j.celrep.2018.03.105CrossRefPubMedPubMedCentral

100.

Okonogi N, Suzuki Y, Sato H et al (2018) Combination therapy of Intravenously Injected Microglia and Radiation Therapy Prolongs Survival in a rat model of spontaneous malignant glioma. Int J Radiat Oncol Biol Phys 102(3):601–608. https://doi.org/10.1016/j.ijrobp.2018.06.018CrossRefPubMed

101.

Olsson M, Hultman K, Dunoyer-Geindre S et al (2016) Epigenetic regulation of tissue-type plasminogen activator in human brain tissue and brain-derived cells. Gene Regul Syst Bio 10:9–13. https://doi.org/10.4137/GRSB.S30241CrossRefPubMedPubMedCentral

102.

Osswald M, Jung E, Sahm F et al (2015) Brain tumour cells interconnect to a functional and resistant network. Nature 528(7580):93–98. https://doi.org/10.1038/nature16071ADSCrossRefPubMed

103.

Ott M, Prins RM, Heimberger AB (2021) The immune landscape of common CNS malignancies: implications for immunotherapy. Nat Rev Clin Oncol 18(11):729–744. https://doi.org/10.1038/s41571-021-00518-9CrossRefPubMed

104.

Ou A, Yung WKA, Majd N (2020) Molecular mechanisms of Treatment Resistance in Glioblastoma. Int J Mol Sci 22(1). https://doi.org/10.3390/ijms22010351

105.

Oyarce C, Vizcaino-Castro A, Chen S et al (2021) Re-polarization of immunosuppressive macrophages to tumor-cytotoxic macrophages by repurposed metabolic Drugs. Oncoimmunology 10(1):1898753. https://doi.org/10.1080/2162402X.2021.1898753CrossRefPubMedPubMedCentral

106.

Padua D, Massague J (2009) Roles of TGFbeta in Metastasis. Cell Res 19(1):89–102. https://doi.org/10.1038/cr.2008.316CrossRefPubMed

107.

Pan Y, Yu Y, Wang X et al (2020) Tumor-Associated macrophages in Tumor Immunity. Front Immunol 11:583084. https://doi.org/10.3389/fimmu.2020.583084CrossRefPubMedPubMedCentral

108.

Paolillo M, Comincini S, Schinelli S (2021) Vitro Glioblastoma models: a journey into the third dimension. Cancers (Basel) 13(10). https://doi.org/10.3390/cancers13102449

109.

Parker JJ, Lizarraga M, Waziri A et al A human glioblastoma organotypic slice culture model for study of Tumor Cell Migration and patient-specific effects of Anti-invasive Drugs. J Vis Exp, 2017(125). https://doi.org/10.3791/53557

110.

Pencheva N, de Gooijer MC, Vis DJ et al (2017) Identification of a Druggable Pathway Controlling Glioblastoma Invasiveness. Cell Rep 20(1):48–60. https://doi.org/10.1016/j.celrep.2017.06.036CrossRefPubMed

111.

Prinz M, Erny D, Hagemeyer N (2017) Ontogeny and homeostasis of CNS myeloid cells. Nat Immunol 18(4):385–392. https://doi.org/10.1038/ni.3703CrossRefPubMed

112.

Pustchi SE, Avci NG, Akay YM et al (2020) Astrocytes decreased the sensitivity of Glioblastoma Cells to Temozolomide and Bay 11-7082. Int J Mol Sci 21(19). https://doi.org/10.3390/ijms21197154

113.

Quereda V, Hou S, Madoux F et al (2018) A cytotoxic three-Dimensional-Spheroid, high-throughput assay using patient-derived glioma stem cells. SLAS Discov 23(8):842–849. https://doi.org/10.1177/2472555218775055CrossRefPubMedPubMedCentral

114.

Ravi VM, Joseph K, Wurm J et al (2019) Human organotypic brain slice culture: a novel framework for environmental research in neuro-oncology. Life Sci Alliance 2(4). https://doi.org/10.26508/lsa.201900305

115.

Ravi VM, Neidert N, Will P et al (2022) T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10. Nat Commun 13(1):925. https://doi.org/10.1038/s41467-022-28523-1ADSCrossRefPubMedPubMedCentral

116.

Reilly KM, Loisel DA, Bronson RT et al (2000) Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet 26(1):109–113. https://doi.org/10.1038/79075CrossRefPubMed

117.

Saha D, Martuza RL, Rabkin SD (2017) Macrophage polarization contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade. Cancer Cell 32(2):253–267e5. https://doi.org/10.1016/j.ccell.2017.07.006CrossRefPubMedPubMedCentral

118.

Sampson JH, Gunn MD, Fecci PE et al (2020) Brain immunology and immunotherapy in brain tumours. Nat Rev Cancer 20(1):12–25. https://doi.org/10.1038/s41568-019-0224-7CrossRefPubMed

119.

Sarkar S, Yang R, Mirzaei R et al (2020) Control of Brain Tumor growth by reactivating myeloid cells with niacin. Sci Transl Med 12(537). https://doi.org/10.1126/scitranslmed.aay9924

120.

Scobie MR, Abood A, Rice CD (2023) Differential transcriptome responses in human THP-1 macrophages following exposure to T98G and LN-18 human glioblastoma secretions: a simplified Bioinformatics Approach to understanding patient-glioma-specific effects on Tumor-Associated macrophages. Int J Mol Sci 24(6). https://doi.org/10.3390/ijms24065115

121.

Setia H, Muotri AR (2019) Brain organoids as a model system for human neurodevelopment and Disease. Semin Cell Dev Biol 95:93–97. https://doi.org/10.1016/j.semcdb.2019.03.002CrossRefPubMedPubMedCentral

122.

Seyfried TN, el-Abbadi M, Roy ML (1992) Ganglioside distribution in murine neural tumors. Mol Chem Neuropathol 17(2):147–167. https://doi.org/10.1007/BF03159989CrossRefPubMed

123.

Shahab SW, Roggeveen CM, Sun J et al (2023) The LIN28B-let-7-PBK pathway is essential for group 3 medulloblastoma Tumor growth and survival. Mol Oncol 17(9):1784–1802. https://doi.org/10.1002/1878-0261.13477CrossRefPubMedPubMedCentral

124.

Shi Y, He X, Wang H et al (2023) Construction of a novel blood brain barrier-glioma microfluidic chip model: applications in the evaluation of permeability and anti-glioma activity of traditional Chinese medicine components. Talanta 253:123971. https://doi.org/10.1016/j.talanta.2022.123971CrossRefPubMed

125.

Srivastava S, Jackson C, Kim T et al (2019) A characterization of dendritic cells and their role in Immunotherapy in Glioblastoma: from preclinical studies to clinical trials. Cancers (Basel) 11(4). https://doi.org/10.3390/cancers11040537

126.

Stessin AM, Clausi MG, Zhao Z et al (2020) Repolarized macrophages, induced by intermediate stereotactic dose radiotherapy and immune checkpoint blockade, contribute to long-term survival in glioma-bearing mice. J Neurooncol 147(3):547–555. https://doi.org/10.1007/s11060-020-03459-yCrossRefPubMed

127.

Straehla JP, Hajal C, Safford HC et al (2022) A predictive microfluidic model of human glioblastoma to assess trafficking of blood-brain barrier-penetrant nanoparticles. Proc Natl Acad Sci U S A 119(23):e2118697119. https://doi.org/10.1073/pnas.2118697119CrossRefPubMedPubMedCentral

128.

Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. https://doi.org/10.1056/NEJMoa043330CrossRefPubMed

129.

Szatmari T, Lumniczky K, Desaknai S et al (2006) Detailed characterization of the mouse glioma 261 Tumor model for experimental glioblastoma therapy. Cancer Sci 97(6):546–553. https://doi.org/10.1111/j.1349-7006.2006.00208.xCrossRefPubMed

130.

Takahashi T (2019) Organoids for Drug Discovery and Personalized Medicine. Annu Rev Pharmacol Toxicol 59:447–462. https://doi.org/10.1146/annurev-pharmtox-010818-021108CrossRefPubMed

131.

Torsvik A, Stieber D, Enger PO et al (2014) U-251 revisited: genetic drift and phenotypic consequences of long-term cultures of glioblastoma cells. Cancer Med 3(4):812–824. https://doi.org/10.1002/cam4.219CrossRefPubMedPubMedCentral

132.

Uhl M, Aulwurm S, Wischhusen J et al (2004) SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 64(21):7954–7961. https://doi.org/10.1158/0008-5472.CAN-04-1013CrossRefPubMed

133.

van Asperen JV, van Bodegraven EJ, Robe P et al (2022) Determining glioma cell invasion and proliferation in ex vivo organotypic mouse brain slices using whole-mount immunostaining and tissue clearing. STAR Protoc 3(4):101703. https://doi.org/10.1016/j.xpro.2022.101703CrossRefPubMedPubMedCentral

134.

Vaubel RA, Tian S, Remonde D et al (2020) Genomic and phenotypic characterization of a Broad Panel of patient-derived xenografts reflects the diversity of Glioblastoma. Clin Cancer Res 26(5):1094–1104. https://doi.org/10.1158/1078-0432.CCR-19-0909CrossRefPubMed

135.

Venkataramani V, Tanev DI, Strahle C et al (2019) Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature 573(7775):532–538. https://doi.org/10.1038/s41586-019-1564-xADSCrossRefPubMed

136.

Venkataramani V, Yang Y, Schubert MC et al (2022) Glioblastoma hijacks neuronal mechanisms for brain invasion. Cell 185(16):2899–2917e31. https://doi.org/10.1016/j.cell.2022.06.054CrossRefPubMed

137.

Venkatesh HS, Johung TB, Caretti V et al (2015) Neuronal activity promotes Glioma Growth through Neuroligin-3 secretion. Cell 161(4):803–816. https://doi.org/10.1016/j.cell.2015.04.012CrossRefPubMedPubMedCentral

138.

Venkatesh HS, Morishita W, Geraghty AC et al (2019) Electrical and synaptic integration of glioma into neural circuits. Nature 573(7775):539–545. https://doi.org/10.1038/s41586-019-1563-yADSCrossRefPubMedPubMedCentral

139.

Watson DC, Bayik D, Storevik S et al (2023) GAP43-dependent mitochondria transfer from astrocytes enhances glioblastoma tumorigenicity. Nat Cancer 4(5):648–664. https://doi.org/10.1038/s43018-023-00556-5CrossRefPubMedPubMedCentral

140.

Wei J, Marisetty A, Schrand B et al (2019) Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target. J Clin Invest 129(1):137–149. https://doi.org/10.1172/JCI121266CrossRefPubMed

141.

Wei Z, Zhang X, Yong T et al (2021) Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles. Nat Commun 12(1):440. https://doi.org/10.1038/s41467-020-20723-xADSCrossRefPubMedPubMedCentral

142.

Woolf Z, Swanson MEV, Smyth LC et al (2021) Single-cell image analysis reveals a protective role for microglia in glioblastoma. Neurooncol Adv 3(1):vdab031. https://doi.org/10.1093/noajnl/vdab031CrossRefPubMedPubMedCentral

143.

Wouters R, Bevers S, Riva M et al (2020) Immunocompetent Mouse models in the search for effective immunotherapy in Glioblastoma. Cancers (Basel) 13(1). https://doi.org/10.3390/cancers13010019

144.

Wu W, Klockow JL, Zhang M et al (2021) Glioblastoma Multiforme (GBM): an overview of current therapies and mechanisms of resistance. Pharmacol Res 171:105780. https://doi.org/10.1016/j.phrs.2021.105780CrossRefPubMedPubMedCentral

145.

Xiang X, Wang J, Lu D et al (2021) Targeting tumor-associated macrophages to synergize Tumor immunotherapy. Signal Transduct Target Ther 6(1):75. https://doi.org/10.1038/s41392-021-00484-9CrossRefPubMedPubMedCentral

146.

Xiao A, Brenneman B, Floyd D et al (2019) Statins affect human glioblastoma and other cancers through TGF-beta inhibition. Oncotarget 10(18):1716–1728. https://doi.org/10.18632/oncotarget.26733CrossRefPubMedPubMedCentral

147.

Xie R, Kessler T, Grosch J et al (2021) Tumor cell network integration in glioma represents a stemness feature. Neuro Oncol 23(5):757–769. https://doi.org/10.1093/neuonc/noaa275CrossRefPubMed

148.

Xie Z, Chen M, Lian J et al (2023) Glioblastoma-on-a-chip construction and therapeutic applications. Front Oncol 13:1183059. https://doi.org/10.3389/fonc.2023.1183059CrossRefPubMedPubMedCentral

149.

Xu J, Zhang J, Zhang Z et al (2021) Hypoxic glioma-derived exosomes promote M2-like macrophage polarization by enhancing autophagy induction. Cell Death Dis 12(4):373. https://doi.org/10.1038/s41419-021-03664-1CrossRefPubMedPubMedCentral

150.

Xu C, Yuan X, Hou P et al (2023) Development of glioblastoma organoids and their applications in personalized therapy. Cancer Biol Med 20(5):353–368. https://doi.org/10.20892/j.issn.2095-3941.2023.0061CrossRefPubMedPubMedCentral

151.

Xue N, Zhou Q, Ji M et al (2017) Chlorogenic acid inhibits glioblastoma growth through repolarizating macrophage from M2 to M1 phenotype. Sci Rep 7:39011. https://doi.org/10.1038/srep39011ADSCrossRefPubMedPubMedCentral

152.

Yang YK, Ogando CR, Wang See C et al (2018) Changes in phenotype and differentiation potential of human mesenchymal stem cells aging in vitro. Stem Cell Res Ther 9(1):131. https://doi.org/10.1186/s13287-018-0876-3CrossRefPubMedPubMedCentral

153.

Yao M, Ventura PB, Jiang Y et al (2020) Astrocytic trans-differentiation completes a multicellular paracrine feedback Loop required for Medulloblastoma Tumor Growth. Cell 180(3):502–520e19. https://doi.org/10.1016/j.cell.2019.12.024CrossRefPubMedPubMedCentral

154.

Ye XZ, Xu SL, Xin YH et al (2012) Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-beta1 signaling pathway. J Immunol 189(1):444–453. https://doi.org/10.4049/jimmunol.1103248CrossRefPubMed

155.

Yi L, Zhou C, Wang B et al (2013) Implantation of GL261 neurospheres into C57/BL6 mice: a more reliable syngeneic graft model for research on glioma-initiating cells. Int J Oncol 43(2):477–484. https://doi.org/10.3892/ijo.2013.1962CrossRefPubMed

156.

Yi Y, Hsieh IY, Huang X et al (2016) Glioblastoma Stem-Like cells: characteristics, Microenvironment, and Therapy. Front Pharmacol 7:477. https://doi.org/10.3389/fphar.2016.00477CrossRefPubMedPubMedCentral

157.

Yu K, Lin CJ, Hatcher A et al (2020) PIK3CA variants selectively initiate brain hyperactivity during gliomagenesis. Nature 578(7793):166–171. https://doi.org/10.1038/s41586-020-1952-2ADSCrossRefPubMedPubMedCentral

158.

Zhang M, Hutter G, Kahn SA et al (2016) Anti-CD47 treatment stimulates phagocytosis of Glioblastoma by M1 and M2 polarized macrophages and promotes M1 polarized macrophages in vivo. PLoS ONE 11(4):e0153550. https://doi.org/10.1371/journal.pone.0153550CrossRefPubMedPubMedCentral

159.

Zhang H, Zhou Y, Cui B et al (2020) Novel insights into astrocyte-mediated signaling of proliferation, invasion and Tumor immune microenvironment in glioblastoma. Biomed Pharmacother 126:110086. https://doi.org/10.1016/j.biopha.2020.110086CrossRefPubMed

160.

Zhang L, Yu H, Yuan Y et al (2020) The necessity for standardization of glioma stem cell culture: a systematic review. Stem Cell Res Ther 11(1):84. https://doi.org/10.1186/s13287-020-01589-8CrossRefPubMedPubMedCentral

161.

Zhou C, Zhang Y, Dai J et al (2016) Pygo2 functions as a prognostic factor for glioma due to its up-regulation of H3K4me3 and promotion of MLL1/MLL2 complex recruitment. Sci Rep 6:22066. https://doi.org/10.1038/srep22066ADSCrossRefPubMedPubMedCentral

162.

Zhou J, Tang Z, Gao S et al (2020) Tumor-Associated macrophages: recent insights and therapies. Front Oncol 10:188. https://doi.org/10.3389/fonc.2020.00188CrossRefPubMedPubMedCentral

163.

Zhou F, Shi Q, Fan X et al (2022) Diverse macrophages constituted the Glioma Microenvironment and Influenced by PTEN Status. Front Immunol 13:841404. https://doi.org/10.3389/fimmu.2022.841404CrossRefPubMedPubMedCentral

Titel: Understanding current experimental models of glioblastoma-brain microenvironment interactions
verfasst von: Niket Yadav
Benjamin W. Purow
Publikationsdatum: 05.01.2024
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 2/2024
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-023-04536-8

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2024

Phase I study targeting newly diagnosed grade 4 astrocytoma with bispecific antibody armed T cells (EGFR BATs) in combination with radiation and temozolomide

Craniospinal irradiation for CNS leukemia: rates of response and durability of CNS control

The role of GammaTile in the treatment of brain tumors: a technical and clinical overview

Laser interstitial thermal therapy for deep-seated perivascular brain tumors is not associated with distal ischemia

The NeuroPoint alliance SRS & tumor QOD registries